AstraZeneca And Abbott Pull The Plug On Cardio Combination Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Saying it was no longer commercially attractive, the partners ended development of mixed dyslipidemia treatment Certriad, a pill that combines a statin and a fibrate, due to the FDA's "complete response" received earlier this year.